Iovance Lifileucel Shows 50% Response Rate in Sarcoma Pilot Trial
Iovance reported a 50% response rate for lifileucel in a soft tissue sarcoma pilot trial.
Related stories
Egetis Therapeutics reports Q3 2026 results
The quarterly report references FDA approval of EMCITATE (triatricol) in the United States; the available text is truncated.
M impact | EQUITY | Nov 05, 2026, 06:33 AM UTC
Skanska Q3 Revenue Reported at SEK 49.4 Billion
Skanska reported third-quarter revenue of SEK 49.4 billion.
M impact | EQUITY | Nov 05, 2026, 06:32 AM UTC
Skanska reports third-quarter 2026 results
Skanska's third-quarter report includes segment-reporting revenue figures.
M impact | EQUITY | Nov 05, 2026, 06:32 AM UTC
Skanska Q3 orders total SEK 68,000 million
L impact | EQUITY | Nov 05, 2026, 06:32 AM UTC
APOTEA Reports Q3 Net Revenue of SEK 1,990.4 Million
M impact | EQUITY | Nov 05, 2026, 06:32 AM UTC
Napatech Reports Q3 2026 Financial Results
M impact | EQUITY | Nov 05, 2026, 06:32 AM UTC